CG Oncology, Inc. Common stockCGONNASDAQ
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +377.78% | +45500.00% | -90.17% | -100.00% | +3774.42% |
| Gross Profit Growth | +0.00% | +0.00% | -90.10% | -240.54% | +106.98% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +0.76% | -2.73% | +14.32% | +14.37% | +14.28% |
| Weighted Average Shares Diluted Growth | +0.76% | -2.73% | +14.32% | +14.37% | +14.28% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +13600.00% | +748.91% | +0.00% | +0.00% | +275.91% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | +160.74% | +278.72% | +25.74% | +24.30% | +32.12% |
| Book Value per Share Growth | +166.53% | +307.99% | +8.35% | +6.11% | +12.10% |
| Debt Growth | -42.75% | -76.89% | +156.44% | +180.00% | +2346.28% |
| R&D Expense Growth | +67.21% | +68.39% | +59.60% | +69.63% | +42.11% |
| SG&A Expenses Growth | +276.18% | +288.35% | +155.69% | +130.24% | +167.71% |